Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures
C.E.P. van Roozendaal(Rotterdam University of Applied Sciences), Leendert H. J. Looijenga(University Medical Center Utrecht), B van Ooijen(Rotterdam University of Applied Sciences), John A. Foekens(National Cancer Centre Japan), J. Wolter Oosterhuis(Erasmus MC Cancer Institute), Cassandra J.C. Claassen(Rotterdam University of Applied Sciences), AD J. M. GILLIS(Rotterdam University of Applied Sciences), J.G.M. Klijn(Rotterdam University of Applied Sciences), S.C. Henzen‐Logmans(Rotterdam University of Applied Sciences), Alexander M.M. Eggermont(University Medical Center Utrecht)
Cited by 65
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k